Quo vadis nanomedicine?

Nanomedicine

Volumn 10, Issue 20, 2015, Pages 3089-3091

  Barz, Matthias ^a   Luxenhofer, Robert ^b   Schillmeier, Michael ^c  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY OF EXETER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER THERAPY; DRUG DELIVERY SYSTEM; HUMAN; IMMUNOTHERAPY; MEDICAL RESEARCH; NANOMEDICINE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; PROCEDURES;

NANOMEDICINE;

EID: 84944879009     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.15.156     Document Type: Review

References (18)

1. Schillmeier M. Caring for social complexity in nanomedicine. Nanomedicine (Lond.) 10(20), 3181-3193 (2015).
2. Weitze MD, Heckl W. Communicating science in the making - challenges and opportunities. Nanomedicine (Lond.) 10(20), 3099-3101 (2015).
3. Barz M. Complexity and simplification in the development of nanomedicines. Nanomedicine (Lond.) 10(20), 3093-3097 (2015).
4. Pour Gashtasbi G. Nanotoxicology and challenges of translation. Nanomedicine (Lond.) 10(20), 3121-3129 (2015).
5. Luxenhofer R. Polymers and nanomedicine: considerations on variability and reproducibility when combining complex systems. Nanomedicine (Lond.) 10(20), 3109-3119 (2015).
6. Guchet X. What's in a word? The person of personalized (nano)medicine. Nanomedicine (Lond.) 10(20), 3167-3179 (2015).
7. Boushehri MAS, Lamprecht A. Nanoparticles as drug carriers: current issues with in vitro testing. Nanomedicine (Lond.) 10(21), doi:10.2217/NNM.15.154 (2015) (In press).
8. Maiolo D, Del Pino P, Metrangolo P, Parak WJ, Baldelli-Bombelli F. Nanomedicine delivery: does protein corona route to the target or off road?. Nanomedicine (Lond.) 10(21), doi:10.2217/NNM.15.163 (2015) (In press).
9. Kubischok N. Assessing the future: past and present visions of nanomedicine. Nanomedicine (Lond.) 10(21), doi:10.2217/NNM.15.176 (2015) (In press).
10. Loeve S. Of drug administration, war and oïkos: mediating cancer with nanomedicines. Nanomedicine (Lond.) 10(21), doi:10.2217/NNM.15.161 (2015) (In press).
11. Pierce RL. The bi-directionality of translational nanomedicine. Nanomedicine (Lond.) 10(21), doi:10.2217/NNM.15.168 (2015) (In press).
12. Bowman DM, Gatof J. Regulatory barriers for nanomedicine: global questions and challenges. Nanomedicine (Lond.) 10(21), doi:10.2217/NNM.15.169 (2015) (In press).
13. Jain KK. Future of nanomedicine: impact on healthcare and society. Nanomedicine (Lond.) 10(21), doi:10.2217/NNM.15.153 (2015) (In press).
14. Santos-Ferreira I, Bettencourt A, Almeida AJ. Nanoparticulate platforms for targeting bone infections: meeting a major therapeutic challenge. Nanomedicine (Lond.) 10(20), 3131-3145 (2015).
15. Owens A, Rannard S. Considerations for clinically-relevant nanomedicine therapies for chronic diseases. Nanomedicine (Lond.) 10(20), 3103-3107 (2015).
16. Lepeltier EA, Nuhn L, Lehr C-M, Zentel R. Not just for tumor targeting: unmet medical needs and opportunities for nanomedicine. Nanomedicine (Lond.) 10(20), 3147-3166 (2015).
17. Bölükbas DA, Meiners S. Lung cancer nanomedicine: potentials and pitfalls. Nanomedicine (Lond.) 10(21), doi:10.2217/NNM.15.155 (2015) (In press).
18. Lyer S, Tietze R, Unterweger H et al. Nanomedical innovation - the SEON-concept for an improved cancer therapy with magnetic nanoparticles. Nanomedicine (Lond.) 10(21), doi:10.2217/NNM.15.159 (2015) (In press).